Cognito Therapeutics vs Truvian Health
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $105M oversubscribed Series C (Mar 2026) led by Morningside Ventures. HOPE pivotal trial fully enrolled. Non-pharmacological Alzheimer's device targeting FDA clearance.
About
Cognito Therapeutics is developing a non-pharmacological treatment for Alzheimer's disease using coordinated gamma-frequency light and sound stimulation — a technology called sensory entrainment that modulates neural oscillations implicated in the disease. The company raised an oversubscribed $105 million Series C in March 2026 led by Morningside Ventures, with its pivotal HOPE clinical trial fully enrolled and topline data expected in late 2026.
Truvian Health received FDA 510(k) clearance for its TruVerus benchtop blood analyzer in Dec 2025; raised $74M in July 2024 and is partnering with Shoppers Drug Mart for commercial rollout.
About
Truvian Health is a San Diego-based medical diagnostics company developing an automated benchtop blood testing platform that delivers lab-accurate results from a few drops of blood in under 30 minutes — without requiring trained laboratory personnel. The company's flagship product, TruVerus, combines multiple blood test modalities into a single compact analyzer designed for point-of-care settings such as physician offices, clinics, urgent care centers, and long-term care facilities that lack on-site labs.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.